UBS Group’s Maze Therapeutics MAZE Stock Holding History

UBS Group’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.8M	Buy	93,898 +65,200	+227%	+$2.88M	﹤0.01%	4654
2025 Q4	$1.19M	Buy	28,698 +905	+3%	+$31.1K	﹤0.01%	5430
2025 Q3	$721K	Sell	27,793 -23,609	-46%	-$399K	﹤0.01%	5821
2025 Q2	$631K	Sell	51,402 -36,662	-42%	-$381K	﹤0.01%	5825
2025 Q1	$970K	Buy	+88,064	New	+$1.06M	﹤0.01%	5305

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

UBS Group's MAZE Position: Q1 2026 in Review

UBS Group increased its Maze Therapeutics (MAZE) stake by 227% in Q1 2026, buying an estimated $2.88M and bringing the position to 93,898 shares worth $2.8M. The position accounts for ﹤0.01% of the portfolio, ranked #4654.

UBS Group first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

UBS Group held 93,898 shares of Maze Therapeutics worth $2.8M as of Q1 2026.
UBS Group bought 65,200 Maze Therapeutics shares in Q1 2026, an estimated $2.88M.
Maze Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4654 holding.
UBS Group first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.